Early tocilizumab and outcomes in acute necrotizing encephalopathy

托珠单抗 医学 置信区间 逻辑回归 内科学 不利影响 回顾性队列研究 改良兰金量表 优势比 儿科 疾病严重程度 脑病 相对风险 前瞻性队列研究 格林-巴利综合征
作者
Velda Xinying Han,Prithuja Poudyal,Vanessa Wan Mun Lee,Arushi Gahlot Saini,Shekeeb S. Mohammad,Sekhar C. Pillai,Gouri Rao Passi,Naveen Sankhyan,Ahmad Rithauddin Mohamed,Lokesh Lingappa,Hiroshi Sakuma,Russell Clive Dale,Ming Jin Lim,Terrence Gerard Sundram Thomas,for The International ANE Study Group
出处
期刊:Developmental Medicine & Child Neurology [Wiley]
被引量:1
标识
DOI:10.1111/dmcn.70454
摘要

AIM: To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). METHOD: This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut-off for outcomes (binary good [mRS 0-2] vs poor [mRS 3-5]) according to day of tocilizumab administration, enabling a dichotomy of 'early' and 'late' treatment groups. Expected outcomes according to ANE severity score (ANE-SS) in early-treatment and late-treatment groups were compared against reference data (conventional therapy, no tocilizumab) for outcomes according to risk category (medium risk: ANE-SS score 2-4; high risk: ANE-SS score ≥5). RESULTS: From 2018 to 2023, 63 children (mean age 6 years 0 months [range: 8 months-15 years 4 months]; 33 males, 30 females) were treated with tocilizumab, alongside corticosteroids in all and intravenous immunoglobulin in 33 (52.4%). Logistic regression defined an optimal treatment window of ≤3.3 days. Compared to the reference data, early tocilizumab (≤ 72 hours after onset, n = 49) was associated with good outcomes in both high-risk (OR = 11.43, 95% confidence interval [CI] = 1.64-127.4, p = 0.01) and medium-risk (OR = 12.80, 95% CI = 2.15-67.8; p = 0.006) ANE-SS categories. No tocilizumab-related adverse events were reported. INTERPRETATION: Early tocilizumab treatment was associated with improved outcomes in severe ANE, with no adverse events, compared to conventional therapy alone.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
anna1992发布了新的文献求助10
刚刚
2秒前
顾矜的应助被老实的盼芙采纳,获得10
3秒前
3秒前
3秒前
ireneadler完成签到,获得积分10
4秒前
Cestbon发布了新的文献求助20
4秒前
4秒前
4秒前
Ziqi发布了新的文献求助100
6秒前
xing_xing的应助被洁净晓绿采纳,获得20
7秒前
科目三的应助被孤独的鸟采纳,获得10
7秒前
李健的小迷弟的应助被West采纳,获得10
7秒前
7秒前
空蒙发布了新的文献求助10
7秒前
研友_VZG7GZ的应助被李琪琪采纳,获得10
7秒前
8秒前
无限觅风发布了新的文献求助10
9秒前
9秒前
jin发布了新的文献求助10
9秒前
gawga发布了新的文献求助10
9秒前
爆米花的应助被aging采纳,获得10
11秒前
anna1992发布了新的文献求助10
11秒前
11秒前
12秒前
NancyDee完成签到,获得积分10
13秒前
13秒前
成精山药完成签到,获得积分10
14秒前
15秒前
15秒前
16秒前
17秒前
18秒前
cookie0312完成签到,获得积分10
18秒前
19秒前
19秒前
19秒前
JamesPei的应助被老实的硬币采纳,获得10
19秒前
徐七鹏发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163614
求助须知:如何正确求助?哪些是违规求助? 9557702
关于积分的说明 21741573
捐赠科研通 7754282
什么是DOI,文献DOI怎么找? 3428275
关于科研通互助平台的介绍 2552989
邀请新用户注册赠送积分活动 2472923